Treatment of hepatic encephalopathy

Indian Journal of Gastroenterology

Volumn 20, Issue SUPPL. 1, 2001, Pages

  Ferenci, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; BENZODIAZEPINE DERIVATIVE; BENZOIC ACID; ENEMA; FLUMAZENIL; LACTITOL; LACTULOSE; MELATONIN; PROTEIN; ZINC;

CLEANING; CLINICAL FEATURE; COLON LAVAGE; CONFERENCE PAPER; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; LIVER DYSFUNCTION; NEUROPATHOLOGY; PATHOGENESIS; PRACTICE GUIDELINE; PROTEIN RESTRICTION;

HEPATIC ENCEPHALOPATHY; HUMANS;

EID: 0035079373     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. An analysis of the causes and prevention of hepatic coma
2. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study
3. Relation of potassium depletion to renal ammonium metabolism and hepatic coma
4. Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A double-blind randomized clinical trial
5. ESPEN guidelines for nutrition in liver disease and transplantation
6. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy
7. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy
8. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy
9. Newer approaches to treatment of hepatic encephalopathy
10. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients
11. The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion
12. The degradation of amino acids, proteins, and blood to shortchain fatty acids in colon is prevented by lactulose
13. Lactitol vs lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double blind, randomized trial
14. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta-analysis
15. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis
16. In vitro and in vivo lactose and lactulose effects on colonic fermentation and portal-systemic encephalopathy parameters
17. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy
18. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design
19. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study
20. Oral L-ornithine L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study
21. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial
22. Critical evaluation of the role of branched chain amino acids in liver disease
23. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis
24. Long-term branched chain amino acid treatment in chronic hepatic encephalopathy
25. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: A randomized controlled trial
26. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy
27. Elevated brain concentrations of 1-4 benzodiazepines in fulminant hepatic failure
28. Ammonia and GABAergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy
29. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: A double blind, randomized, placebo controlled multicentre study
30. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: A double-blind pragmatic randomized, placebo study
31. Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial
32. Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study
33. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis - An Italian multicenter double-blind, placebo controlled, cross-over study
34. Serum zinc levels in hepatic encephalopathy
35. Expression and regulation of brain metallothionein
36. Divalent cations modulate the transient outward current in rat ventricular myocytes
37. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis
38. Overt hepatic encephalopathy precipitated by zinc deficiency
39. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial
40. High prevalence of sleep disturbance in cirrhosis
41. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis